



KNOWLEDGE SHARING AND CAPACITY BUILDING

- This *new one-day program* was dedicated to deep-dive discussions on the topic of comparability. Topics will change every year.
- Viral vector-based gene therapies, the analytical toolkit, and process
 & product understanding continue to mature and analytical
 comparability exercises can be sufficient in many cases.
 - Challenges for assessing the comparability of CGTP include *complex products and a limited body of knowledge to date* in terms of clinical and manufacturing experience.
 - Cellular products need a tailored approach whether autologous or allogeneic. Paired starting material approach is *useful but needs further consideration* to account for the inherent variability of cellular starting material.

CGTP Summit 2023 BY THE NUMBERS



Attendee Participants

In-Person - 120 Virtual - 200

First Time - 123



Regulators Participation

1/.



Company Participation

80



Country Participation

17

Afghanistan | Australia | Belgium | Canada | China | Denmark | France | Germany | Ireland | Italy | Netherlands | Portugal | Singapore | South Korea | Switzerland | United Kingdom | United States



